Clinical trial
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00019929 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019929 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Individualized Mutant p53 Peptide-Pulsed Cultured Autologous Dendritic Cells in the Adjuvant Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer After Standard Therapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Procedure |
| Interventions | mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy |
| Start date | Aug 1, 2000 |
| Completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: